For people living with depression that haven't responded to standard treatment, the question of what comes next can feel urgent. Ketamine has become one of the most discussed answers to that question, and one of the most misunderstood.
This month, the mental health innovation organisation Hemingway published an independent assessment of ketamine for treatment-resistant depression, as part of its Innovation Atlas series. It's one of the most balanced overviews we've read, so we wanted to share the key points, along with our own perspective as a clinical research site.
Read the full report: Anna Zecharia and Steve Duke, Hemingway Innovation Atlas: Ketamine, The Hemingway Report, November 2026. Available at thehemingwayreport.com.
In short: ketamine has opened up genuinely new possibilities, but there is still a lot we don't know about who it helps, for how long, and how best to use it.
A different kind of antidepressant
Ketamine has been used as an anaesthetic for decades. Its story in mental health began in 2000, when a small study found it could ease symptoms of depression within hours. A further trial in 2006 showed similar rapid effects in people whose depression hadn't responded to other treatments.
That was a striking finding. Most antidepressants take several weeks to have an effect, and for many people they don't work well enough. Ketamine also works differently: rather than acting mainly on serotonin, like most antidepressants, it acts on the brain's glutamate system, which plays a central role in learning and forming new connections between brain cells.
That difference is one reason researchers are so interested in it. It opened up a new way of thinking about how depression might be treated.
Three ways ketamine reaches patients
The report describes three main routes, each with a different evidence base.
Esketamine nasal spray. Developed by Janssen and sold as Spravato, esketamine is made from one of the two molecular forms of ketamine. It is the only ketamine-based product with a licence for depression, backed by a full programme of regulatory trials. Health systems have reached different conclusions about whether it offers value for money: it is funded in Australia and Germany and accepted in Scotland, but NICE has not recommended it for use in England and Wales.
Intravenous (IV) ketamine. This is generic ketamine, given by infusion in specialist clinics and used "off-label" for depression. Research shows rapid effects, but most of it has been led by academic researchers rather than a drug company. Because ketamine is a cheap, generic medicine, no company has a strong financial reason to fund the large, long-term trials that health systems usually want. Norway has funded it nationally in specialist care since 2025, while collecting more evidence.
At-home ketamine. Mainly in the United States, some telehealth companies supply ketamine for people to take at home, with varying doses and levels of supervision. The report notes that this market has grown without the kind of controlled trials normally required, and that the US Food and Drug Administration has warned about the risks of taking it without a clinician present.
Intramuscular (IM) ketamine. The Hemmingway report focuses on nasal esketamine, IV infusions and at-home use. But there is another route worth knowing about: intramuscular ketamine, given as a single injection into a muscle, usually the upper arm. This is what we do here at Mirabilis Health. It doesn't need a drip, the body absorbs it well, and its effects begin within minutes. For these reasons, IM ketamine is often used in ketamine-assisted psychotherapy, where the medicine is combined with preparation and integration sessions with a therapist. The research base for IM ketamine is smaller than for IV ketamine or esketamine. Early studies suggest it may have similar antidepressant effects to IV ketamine, but larger trials are needed, so many of the open questions in this article apply to it too.
The honest limitations
Ketamine is not a miracle cure, and the report is clear about this. Not everyone responds. For those who do, the benefit often fades over time, so treatment may need to be repeated. Because of short-term side effects and the potential for misuse, clinic doses are given under supervision.
The report highlights several questions that still don't have clear answers:
Who will benefit? There is not yet a reliable way to predict who will respond, although researchers are working on it.
How long will it last? We need better evidence on how long improvements hold and what helps them last.
When should treatment stop? There is little guidance on when it is safe to finish a course.
Is improvement the same as recovery? Feeling better quickly matters, but so does long-term wellbeing.
These are exactly the kinds of questions patients ask us, and they deserve honest answers, including "we don't know yet" where that's the truth.
Access, cost and fairness
One of the report's strongest points is that access to ketamine depends heavily on where people live and whether they can pay. In one US study it cites, people living 50 miles or more from a treatment centre were far less likely to start esketamine than those living close by.
In the UK, NICE's decision not to recommend esketamine means it isn't routinely available on the NHS in England and Wales, and Northern Ireland generally follows NICE guidance on new medicines. IV ketamine is available through a small number of NHS services, sometimes on a self-pay basis, and through private clinics. The report notes that at one NHS service in Oxford, the drug itself costs around £1 per dose, while each supervised session is charged at £265. Most of the cost lies in the time, staff and monitoring needed to deliver it safely.
This tension between cost and access is one we feel keenly. Effective care shouldn't depend on someone's postcode or bank balance.
What the report recommends
The authors argue that the biggest barrier isn't the science itself. It's the gap between the evidence being produced and the decisions health systems need to make. They suggest starting with those decisions and working backwards: agreeing what funders and health services need to know, mapping what existing research can already answer, and then filling the gaps that could genuinely change decisions. Importantly, they want patients involved in defining what a meaningful benefit looks like.
The timing matters. Several head-to-head trials comparing IV ketamine and esketamine are due to report between 2027 and 2030, and new longer-acting forms of ketamine are in development.
The report also sets out safeguards it believes should apply whoever is paying, in the NHS or privately:
Treatment should be started by a psychiatrist
Patients should be monitored after every dose given in a clinic
There should be a clear plan for any treatment taken at home
Outcomes should be recorded
There should be clear rules for when to continue and when to stop
Our perspective
We welcome this report. It is honest about both the promise and the uncertainty, and that's the spirit in which we try to work.
At Mirabilis Health, we are a clinical research site first. We believe new approaches to mental health deserve to be explored carefully, with proper medical oversight and a willingness to follow the evidence wherever it leads. The safeguards the report describes, including psychiatrist-led care, careful monitoring and recording outcomes, reflect principles we hold to across our work.
We're also struck by one of the report's closing thoughts: that how we learn to evaluate ketamine could shape how future treatments, including psilocybin, are assessed and adopted. As a site preparing for psychedelic research here in Northern Ireland, that's a conversation we want to be part of.
There is still a great deal to learn. We think that's a reason for careful curiosity, not for either hype or dismissal.